Cerebro-Spinal Fluid N-Glycoproteomics for Early Diagnosis in Alzheimer’s Disease
This work aims at exploring the human CSF (Cerebrospinal fluid) N-glycome by MALDI MS techniques, in order to assess specific glycosylation pattern(s) in patients with Alzheimer’s disease and in subjects with mild cognitive impairment (MCI), these last as potential AD patients at a pre-dementia stage. Noteworthy, all the MCI patients that converted to AD within the clinical follow-up, had an abnormal CSF glycosylation profile. Based on the studied cohort, CSF glycosylation changes at an early phase of the whole biomolecular misregulation on AD.
This finding points to CSF N-glycome analyses as promising tool to enhance early detection of AD and also suggesting alternative therapeutics target molecules, such as specific glyco-enzymes.